Figure 5.

Analysis of antitumor properties of GcMAF-RF. (A) Effect of tumor cell culture medium on the ability of GcMAF-RF to activate murine PMs. Mean ± SD values are shown (n = 4). * significant differences from the corresponding control, p < 0.05 (Mann–Whitney U test). (B) Effects of the Karanahan therapy alone and Karanahan therapy in combination with GcMAF-RF in mice with Lewis carcinoma. Mean ± SD values are presented. (C) Loss of specific phagocytic activity by murine PMs due to treatment with tumor lysate. Macrophages were either treated with GcMAF-RF alone, GcMAF-RF and Lewis carcinoma tumor lysate, GcMAF-RF and Lewis carcinoma tumor lysate obtained from mice on day 7 after Karanahan therapy, or first exposed to corresponding tumor lysates and then activated by GcMAF-RF. PM pretreatment scheme is given in Supplementary Data S2, Figure S3. The values of PM activation indices (Mean ± SD) are presented. * significant differences from GcMAF-RF, p < 0.05 (Mann–Whitney U test). (D) Schematic representation of the search for regimens of PM treatment. (E) Phagocytic activity of PMs in the absence of additional treatments (control), treated with GcMAF-RF three, five, or six times with a 24-h interval, and treated with a Lewis carcinoma lysate obtained from mice on day 7 after the Karanahan therapy. The values of PM activation indices (Mean ± SD) are shown. * significant differences from the control, p < 0.05 (Mann–Whitney U test).